Matches in Wikidata for { <http://www.wikidata.org/entity/Q92831974> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- Q92831974 description "artículu científicu espublizáu n'agostu de 2019" @default.
- Q92831974 description "im August 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92831974 description "scientific article published on 23 August 2019" @default.
- Q92831974 description "wetenschappelijk artikel" @default.
- Q92831974 description "наукова стаття, опублікована 23 серпня 2019" @default.
- Q92831974 name "Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer" @default.
- Q92831974 name "Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer" @default.
- Q92831974 type Item @default.
- Q92831974 label "Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer" @default.
- Q92831974 label "Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer" @default.
- Q92831974 prefLabel "Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer" @default.
- Q92831974 prefLabel "Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer" @default.
- Q92831974 P1433 Q92831974-6D7465FF-2276-4F30-B829-19AAEAE54D73 @default.
- Q92831974 P1476 Q92831974-551D92A0-2DD5-425C-A6E4-C339E43B33F3 @default.
- Q92831974 P2093 Q92831974-12011864-2929-4345-A97B-55070C58FB10 @default.
- Q92831974 P2093 Q92831974-86DEF298-5157-46CC-8706-7EBCA063EFE0 @default.
- Q92831974 P2093 Q92831974-977A44DB-8574-4AE2-AA61-AB8770DA67B7 @default.
- Q92831974 P2093 Q92831974-A7014690-E87E-4253-B6A2-FBB1FE34FF24 @default.
- Q92831974 P2093 Q92831974-A8E3AC0E-A87A-4F4D-887F-3713F65E8B17 @default.
- Q92831974 P2093 Q92831974-E3AE202E-00D6-4328-99F6-9AD9B5730FB9 @default.
- Q92831974 P2093 Q92831974-FAD1BB98-3885-4457-88C4-47ABD177A2A9 @default.
- Q92831974 P275 Q92831974-337316fe-4f77-4323-8807-42d77d42fb17 @default.
- Q92831974 P2860 Q92831974-0BD929DC-925E-4661-A8CD-687D8FB0892D @default.
- Q92831974 P2860 Q92831974-50FBA645-B0E8-4621-8296-71F326BDD1F9 @default.
- Q92831974 P2860 Q92831974-5AA753F2-9457-4DC7-9FE5-F7EE42E6A6B2 @default.
- Q92831974 P2860 Q92831974-679A8FB3-8483-4B19-B51D-11EE00DDA751 @default.
- Q92831974 P2860 Q92831974-708D0C48-D471-4AE2-9580-C4083479D8B7 @default.
- Q92831974 P2860 Q92831974-B0ABC201-75E7-4960-805F-FAC384AB414B @default.
- Q92831974 P2860 Q92831974-D828FBA7-0C2D-4F13-9068-EC9F7D3851B5 @default.
- Q92831974 P2860 Q92831974-E21B6EF9-B24E-49D8-B180-AD2972176B48 @default.
- Q92831974 P2860 Q92831974-F3E1CBE4-4EDF-4AD9-B4F8-2DF10AF60D41 @default.
- Q92831974 P304 Q92831974-ADF6C335-9833-4F7D-AAE8-A67CC16B3B49 @default.
- Q92831974 P31 Q92831974-184C8396-CD9D-4E4E-9898-4321B347BA8E @default.
- Q92831974 P356 Q92831974-BABFD0DF-4B6A-45D8-B4C4-55F6F4F5B135 @default.
- Q92831974 P433 Q92831974-3D0BB2B4-B4F9-4531-A575-E87492C8CA87 @default.
- Q92831974 P478 Q92831974-0E595F40-5488-4021-A521-B6B070EFE3DC @default.
- Q92831974 P50 Q92831974-C3D934EC-66F6-464C-8FCC-0B834DAEE6C5 @default.
- Q92831974 P577 Q92831974-F37DEF84-F805-463E-9ECE-7F3CD9446C34 @default.
- Q92831974 P6216 Q92831974-516c14c4-7045-494a-87b1-bff3abe100b1 @default.
- Q92831974 P698 Q92831974-35893784-9F6F-4640-BA8A-8ED0063872F7 @default.
- Q92831974 P921 Q92831974-76F8E687-4E01-4F05-9575-CEEE0EA2E4F4 @default.
- Q92831974 P921 Q92831974-7FEC8E37-2C39-4ED6-A845-5F8326C2D60F @default.
- Q92831974 P932 Q92831974-160F2352-3370-4748-9A08-D11AE8416FFE @default.
- Q92831974 P356 THEONCOLOGIST.2018-0686 @default.
- Q92831974 P698 31444293 @default.
- Q92831974 P1433 Q2122327 @default.
- Q92831974 P1476 "Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer" @default.
- Q92831974 P2093 "Arthur Winer" @default.
- Q92831974 P2093 "Asya Varshavsky" @default.
- Q92831974 P2093 "Fern Anari" @default.
- Q92831974 P2093 "Nicole Bubes" @default.
- Q92831974 P2093 "Pooja Ghatalia" @default.
- Q92831974 P2093 "Vineela Kasireddy" @default.
- Q92831974 P2093 "Yang Liu" @default.
- Q92831974 P275 Q24082749 @default.
- Q92831974 P2860 Q28262647 @default.
- Q92831974 P2860 Q28314934 @default.
- Q92831974 P2860 Q34943776 @default.
- Q92831974 P2860 Q38621228 @default.
- Q92831974 P2860 Q38654591 @default.
- Q92831974 P2860 Q49887005 @default.
- Q92831974 P2860 Q50876217 @default.
- Q92831974 P2860 Q55085516 @default.
- Q92831974 P2860 Q91081821 @default.
- Q92831974 P304 "1416-1419" @default.
- Q92831974 P31 Q13442814 @default.
- Q92831974 P356 "10.1634/THEONCOLOGIST.2018-0686" @default.
- Q92831974 P433 "11" @default.
- Q92831974 P478 "24" @default.
- Q92831974 P50 Q4118647 @default.
- Q92831974 P577 "2019-08-23T00:00:00Z" @default.
- Q92831974 P6216 Q50423863 @default.
- Q92831974 P698 "31444293" @default.
- Q92831974 P921 Q13896859 @default.
- Q92831974 P921 Q783644 @default.
- Q92831974 P932 "6853126" @default.